成熟商业化团队及分销网络构建，海外订单爆发式增长 精锋医疗于2017年5月在深圳创立，是中国自主研发手术机器人领域的深耕者，为中国首家、全球第二 家同时取得多孔腔镜手术机器人、单孔腔镜手术机器人及自然腔道手术机器人注册审批的公司，已构建 多孔+单孔+远程系统的"三合一"外科手术解决方案。公司全球首创的单多孔手术机器人超级系统 MSP2000已于2025年10月获得CE证，为全球手术机器人的技术演进与临床应用提供创新范本。 24年国内厂商销量第一，持续落地中国顶级医院圈层 自精锋多孔腔镜手术机器人于2022年12月商业化以来，于2024年在中国售出了20台精锋多孔腔镜手术机 器人，在国内手术机器人制造商中排名第一，临床应用范围已覆盖全国30个省份，超过220家医院，包 括国内顶尖三甲医院乃至多个省份的县域基层医院，实现了"省-市-县"三级医院网络的全覆盖。伴随国 内销量大幅增长以及海外的商业化，公司总收入由2023年的0.48亿元增加至2024年的1.6亿元，并由 2024H1的0.30亿元增加至2025H1的1.49亿元。 国泰海通证券发布研报称，首次覆盖精锋医疗-B(02675)给予评级为"增持"。预测公司 ...

自精锋多孔腔镜手术机器人于2022年12月商业化以来，于2024年在中国售出了20台精锋多孔腔镜手术机 器人，在国内手术机器人制造商中排名第一，临床应用范围已覆盖全国30个省份，超过220家医院，包 括国内顶尖三甲医院乃至多个省份的县域基层医院，实现了"省-市-县"三级医院网络的全覆盖。伴随国 内销量大幅增长以及海外的商业化，公司总收入由2023年的0.48亿元增加至2024年的1.6亿元，并由 2024H1的0.30亿元增加至2025H1的1.49亿元。 智通财经APP获悉，国泰海通证券发布研报称，首次覆盖精锋医疗-B(02675)给予评级为"增持"。预测公 司2025-2027年的收入分别为4.32、8.11、12.36亿元，参考可比公司，考虑公司产品布局领先，海外进 展迅速，给予公司2026年35XPS，对应目标价73.20元/79.57港元（汇率为1港元=0.92人民币）。 国泰海通证券主要观点如下： 国产手术机器人引领者，持续革新推动技术进步 精锋医疗于2017年5月在深圳创立，是中国自主研发手术机器人领域的深耕者，为中国首家、全球第二 家同时取得多孔腔镜手术机器人、单孔腔镜手术机器人及自然腔道手术 ...

Core Viewpoint - Shenzhen Jingfeng Medical Technology Co., Ltd. successfully listed on the Hong Kong Stock Exchange with an opening price of HKD 43.24 per share, achieving a market capitalization of HKD 23 billion on its first trading day, reflecting strong investor interest in the surgical robotics sector [3]. Company Overview - Jingfeng Medical specializes in advanced surgical robots, including multi-port and single-port laparoscopic surgical robots. The company received EU CE certification for its SP1000 and MSP2000 systems, marking a significant milestone as the first integrated surgical robot platform from China [5][11]. - The company was founded by alumni of Tianjin University, Wang Jianchen and Gao Yuanqian, and has attracted investments from notable firms such as Lenovo Star, Sequoia China, and Hillhouse Capital [5][11]. Investment Insights - Lenovo Star, the only early-stage investment firm with a systematic focus on healthcare, has seen a nearly 20-fold return on its investment of approximately HKD 28 million following Jingfeng Medical's successful IPO [5][12]. - The investment decision was based on a thorough analysis of the surgical robotics market, with a particular focus on the competitive landscape and the technical capabilities of Jingfeng Medical's team [10][14]. Market Potential - The laparoscopic surgical robot market is viewed as a critical battleground, with multi-port systems being essential for competitive positioning. The team behind Jingfeng Medical is recognized for its strong technical foundation and innovative capabilities [7][15]. - The company has expanded its clinical applications across 30 provinces in China, partnering with over 220 hospitals, including top-tier hospitals and grassroots healthcare facilities [11]. Technological Advancements - Jingfeng Medical's "Jingfeng Cloud" system aims to overcome geographical limitations in surgical capabilities, achieving over 500 surgeries globally and setting a Guinness World Record for the longest-distance surgery [11][18]. - The company is also focusing on enhancing AI capabilities in its surgical robots, with experimental validations indicating significant advancements in surgical efficiency and safety [18]. Strategic Positioning - Lenovo Star's investment strategy emphasizes the integration of AI and robotics in healthcare, aiming to identify and support innovative companies that can redefine industry standards [17][18]. - The firm has established a unique position by balancing investments in both technology and healthcare, allowing it to capitalize on emerging opportunities in the medical sector [16][17].